Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Mufg Securities Americas Inc. made a modest splash in the biotech pool, acquiring 1,554 shares of Regeneron Pharmaceuticals ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

On Wednesday, Leerink Partners began coverage of Kalaris (NASDAQ: KLRS), currently trading at $4.79 with a market capitalization of $89.6 million, assigning the biotech firm an Outperform rating ...

On Thursday, Leerink Partners maintained a positive outlook on GoodRx Holdings Inc. (NASDAQ: GDRX) shares, reiterating an Outperform rating and a $9.00 price target. The firm’s analysts ...